[Experience with the clinical study of cordaron].
Complex examination including continuous long-term observation by means of a computer showed that because of a wide spectrum of action cordaron is among the effective agents for the treatment of ischemic heart disease. The capacity of cordaron to reduce the zone of myocardial damage makes its use expedient in the acute period of myocardial infarction. Long-term treatment of patients suffering from chronic ischemic disease of the heart with cordaron raises the tolerance to physical exercise and improves myocardial nutrition. The coronarolytic effect of cordaron is evidently associated to a definite measure with the action of the agent on adenosine metabolism, which is manifested in an increase in its production and inhibition of its inactivation.
D000328:Adult; D000368:Aged; D000638:Amiodarone / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001572:Benzofurans / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy; D004562:Electrocardiography / Q000379:methods; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy
D000889:Anti-Arrhythmia Agents; D001572:Benzofurans; D000638:Amiodarone
Opyt klinicheskogo izucheniia kordarona.